Department of Dermatology, New Orleans, LA;
Louisiana State University School of Medicine, New Orleans, LA.
Skinmed. 2022 Oct 31;20(5):338-342. eCollection 2022.
Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer and accounts for approximately 25% of nonmelanoma skin cancers (NMSC). Although the majority of cutaneous SCC lesions have been treated successfully by surgical excision, cryotherapy, electrodessication, or Mohs micrographic surgery, some locally advanced SCC patients are either inoperable, have been metastasized, or both. In such patients, treatment is more challenging due to limited options. We reviewed the literature to describe the mechanism of anti-PD1 agents in cancer therapy and current PD-1 blockade immunotherapy trials in cutaneous SCC. Currently, cemiplimab is the only anti-PD1 agent approved by the Food and Drug Administration for the treatment of locally advanced or metastatic SCC. This review described other anti-PD1 agents, such as pembrolizumab and nivolumab, that have depicted promising effects in advanced SCC, resulting in reduction of tumor size with minimal adverse effects. Immunotherapy targeting the PD-1-PD-L1 axis must be considered for advanced cutaneous SCC patients that are refractory to first-line of procedural treatment options.
皮肤鳞状细胞癌（SCC）是第二常见的皮肤癌类型，约占非黑色素瘤皮肤癌（NMSC）的 25%。尽管大多数皮肤 SCC 病变已通过手术切除、冷冻疗法、电干燥或 Mohs 显微外科手术成功治疗，但一些局部晚期 SCC 患者因无法手术、转移或两者兼而有之而治疗更为困难。我们查阅了文献，以描述抗 PD-1 药物在癌症治疗中的作用机制，以及目前在皮肤 SCC 中的 PD-1 阻断免疫治疗试验。目前，cemiplimab 是唯一一种被美国食品和药物管理局批准用于治疗局部晚期或转移性 SCC 的抗 PD-1 药物。本综述描述了其他抗 PD-1 药物，如 pembrolizumab 和 nivolumab，在晚期 SCC 中显示出了有前景的效果，导致肿瘤缩小，副作用最小。对于对一线手术治疗选择耐药的晚期皮肤 SCC 患者，必须考虑针对 PD-1-PD-L1 轴的免疫治疗。
